Fierce Biotech November 10, 2023
RapidAI is showing no signs of slowing down after racking up a trio of FDA clearances since the start of the year.
The latest of the agency nods was bestowed upon an artificial intelligence-powered module that’s designed to spot signs of possible subdural hematomas in non-contrast CT scans of the brain.
The FDA clearance of Rapid SDH, announced by RapidAI on Thursday, makes the module available to hospitals in the U.S., where cases of subdural hematoma current carry a mortality rate between 40% and 60% and are expected to grow in prevalence by almost 80% within the next 20 years, according to the company.
Rapid SDH’s AI was trained using hundreds of previous patient scans to spot potential indicators of...
Today's Sponsors
Today's Sponsor